{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:01:59Z","timestamp":1790762519130,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13139-026-01028-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:43:52Z","timestamp":1778553832000},"page":"600-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of [177Lu]Lu-DOTATATE in Neuroendocrine Tumors at a Tertiary Cancer Center in Jordan: A Multinational Arab Cohort"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Saad","family":"Abdlkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhuha","family":"Al-Adhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Moghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ruzzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al-Alalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Rammahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rula","family":"Amarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Al-Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Shamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asem","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1028_CR1","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/ERC-20-0036","volume":"27","author":"G Rindi","year":"2020","unstructured":"Rindi G, Inzani F. Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer. 2020;27:R211\u20138.","journal-title":"Endocr Relat Cancer"},{"key":"1028_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000481390","volume":"33","author":"G Kl\u00f6ppel","year":"2017","unstructured":"Kl\u00f6ppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med. 2017;33:324\u201330.","journal-title":"Visc Med"},{"key":"1028_CR3","doi-asserted-by":"publisher","first-page":"19245","DOI":"10.18632\/oncotarget.24983","volume":"9","author":"A Chauhan","year":"2018","unstructured":"Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, et al. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018;9:19245\u201354.","journal-title":"Oncotarget"},{"key":"1028_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17446651.2023.2237593","volume":"18","author":"S Pathak","year":"2023","unstructured":"Pathak S, Starr JS, Halfdanarson T, Sonbol MB. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. 2023;18:377\u201385.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1028_CR5","first-page":"71","volume":"14","author":"MS Hofman","year":"2012","unstructured":"Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14:71\u201381.","journal-title":"Discov Med"},{"key":"1028_CR6","doi-asserted-by":"crossref","unstructured":"Rossi RE, Massironi S. The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11133794"},{"key":"1028_CR7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68 Ga-DOTATATE Compared with < sup>111 In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med. 2016;57:872\u20138.","journal-title":"J Nucl Med"},{"key":"1028_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61\u201372.","journal-title":"Lancet Oncol"},{"key":"1028_CR9","doi-asserted-by":"publisher","first-page":"204201881880469","DOI":"10.1177\/2042018818804698","volume":"10","author":"M Tsoli","year":"2019","unstructured":"Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1028_CR10","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.3390\/cancers14215248","volume":"14","author":"A Chauhan","year":"2022","unstructured":"Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D. Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers (Basel). 2022;14:5248.","journal-title":"Cancers (Basel)"},{"key":"1028_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","volume":"16","author":"A Faggiano","year":"2017","unstructured":"Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16:1149\u201361.","journal-title":"Expert Opin Drug Saf"},{"key":"1028_CR12","doi-asserted-by":"crossref","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [<\u2009sup>177\u2009Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 2024;403:2807\u201317.","DOI":"10.1016\/S0140-6736(24)00701-3"},{"key":"1028_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of < sup>177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"1028_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025;66:757\u201363.","journal-title":"J Nucl Med"},{"key":"1028_CR15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.semnuclmed.2025.07.005","volume":"55","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Brink A, Lee ST, De Los Reyes A, Paez D, Craviolatti PS, et al. Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. Semin Nucl Med. 2025;55:1032\u201344.","journal-title":"Semin Nucl Med"},{"key":"1028_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2021;112:90\u20132.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"1028_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1 \u2013 Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"key":"1028_CR18","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A, Mohamedkhair A. Current Status of Theranostics in Jordan. Nucl Med Mol Imaging (2010). 2019;53:7\u201310.","DOI":"10.1007\/s13139-018-0562-5"},{"key":"1028_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33:115\u201354.","journal-title":"Endocr Pathol"},{"key":"1028_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146:1533\u201343.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1028_CR21","unstructured":"Baum RP, Fricke JG, Ruhwedel T, Amthauer H, Azorin-Vega EP, H\u00f6rsch D et al. Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors. J Neuroendocrinol n\/a:e70103"},{"key":"1028_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4183\/aeb.2024.388","volume":"20","author":"AS Abdlkadir","year":"2024","unstructured":"Abdlkadir AS, Ruzzeh S, Al-Ibraheem A. Molecular Imaging and Therapy in an Unresponsive Case with Multisystemic Metastatic Ileal Neuroendocrine Tumor. Acta Endocrinol (Buchar). 2024;20:388\u201392.","journal-title":"Acta Endocrinol (Buchar)"},{"key":"1028_CR23","doi-asserted-by":"crossref","unstructured":"Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD et al. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor\u2013Expressing Neuroendocrine Tumors: The First US Phase 2 Experience. Pancreas. 2014;43.","DOI":"10.1097\/MPA.0000000000000113"},{"key":"1028_CR24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2967\/jnumed.123.265703","volume":"65","author":"ES Delpassand","year":"2024","unstructured":"Delpassand ES, Yazdi SM, Ghantoji S, Nakasato A, Strickland C, Nunez R, et al. Effectiveness and Safety of Retreatment with < sup>177 Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. J Nucl Med. 2024;65:746\u201352.","journal-title":"J Nucl Med"},{"key":"1028_CR25","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1007\/s00259-022-05771-3","volume":"49","author":"D Clement","year":"2022","unstructured":"Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, et al. Efficacy and safety of 177Lu\u2013DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. Eur J Nucl Med Mol Imaging. 2022;49:3529\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1028_CR26","doi-asserted-by":"crossref","unstructured":"Demirci E, Kabasakal L, Toklu T, Ocak M, Sahin OE, Alan-Selcuk N et al. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun. 2018;39.","DOI":"10.1097\/MNM.0000000000000874"},{"key":"1028_CR27","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3390\/cancers17182992","volume":"17","author":"Y-i Kim","year":"2025","unstructured":"Kim Y-i, Suh HY, Kang Y, Cho H, Hyun SH, Song YS, et al. First Real-World Evidence on the Safety and Effectiveness of LutatheraTM for Treating Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Insights from Post-Marketing Surveillance. Cancers (Basel). 2025;17:2992.","journal-title":"Cancers (Basel)"},{"key":"1028_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jhbp.1101","volume":"29","author":"A Kudo","year":"2022","unstructured":"Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, et al. Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial. J Hepato-Biliary-Pancreat Sci. 2022;29:487\u201399.","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"key":"1028_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0042-1755412","volume":"21","author":"M Kalantarhormozi","year":"2022","unstructured":"Kalantarhormozi M, Hassanzadeh S, Rekabpour SJ, Ravanbod MR, Jafari E, Amini A, et al. Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment. World J Nucl Med. 2022;21:215\u201321.","journal-title":"World J Nucl Med"},{"key":"1028_CR30","doi-asserted-by":"crossref","unstructured":"Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol. 2020;94.","DOI":"10.1259\/bjr.20201041"},{"key":"1028_CR31","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/jcm14072384","volume":"14","author":"SE Campos Ram\u00edrez","year":"2025","unstructured":"Campos Ram\u00edrez SE, Andr\u00e9s Garc\u00eda A, Blanco Abad C, Gomila Pons P, G\u00f3mez Mugarza P, Ruffini Egea SE, et al. Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors. J Clin Med. 2025;14:2384.","journal-title":"J Clin Med"},{"key":"1028_CR32","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.esmogo.2025.100146","volume":"8","author":"LM Altus","year":"2025","unstructured":"Altus LM, Forster JC, Mercurio J, Kitchener M, Corsini N, Nenke M, et al. The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival. ESMO Gastrointest Oncol. 2025;8:100146.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1028_CR33","doi-asserted-by":"publisher","first-page":"e13464","DOI":"10.1111\/jne.13464","volume":"37","author":"RV Parghane","year":"2025","unstructured":"Parghane RV, Basu S. Toxicity manifestations encountered in peptide receptor radionuclide therapy setting. J Neuroendocrinol. 2025;37:e13464.","journal-title":"J Neuroendocrinol"},{"key":"1028_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/bjc.1998.635","volume":"78","author":"E Baudin","year":"1998","unstructured":"Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78:1102\u20137.","journal-title":"Br J Cancer"},{"key":"1028_CR35","first-page":"118","volume":"3","author":"RE Rossi","year":"2015","unstructured":"Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, et al. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118.","journal-title":"Ann Transl Med"},{"key":"1028_CR36","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2967\/jnumed.124.267497","volume":"65","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem A, Abdlkadir A, Al-Adhami D, Herrmann K. [(177)Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid. J Nucl Med. 2024;65:1494.","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01028-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-026-01028-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01028-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:16:57Z","timestamp":1790759817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-026-01028-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s13139-026-01028-1","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of our institution (IRB No. 24 KHCC 234), and the requirement for written consent was waived by the institutional review board. All procedures performed in studies involving human participants were in accordance with the Helsinki Declaration as revised in 2024 and its later amendments.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was not required as the patient\u2019s clinical data and images were fully anonymized, and no personally identifiable information is included in this article.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akram Al-Ibraheem is an editorial board member of Nuclear Medicine and Molecular Imaging Journal but was not involved in the review process. Ahmed Saad Abdlkadir, Dhuha Al-Adhami, Serin Moghrabi, Saad Ruzzeh, Hasan Al-Alalawi, Mohammed Al-Rammahi, Rula Amarin, Kamal Al-Rabi, Omar Shamieh, Issa Mohamad, Hikmat Abdel-Razeq, and Asem Mansour declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they did not use any type of generative AI in the writing of this manuscript.","order":4,"name":"Ethics","label":"Declaration of generative AI in scientific writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}